Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects
NCT03520972
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
251
Enrollment
OTHER
Sponsor class
Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG:
PB-119 75ug
DRUG:
PB-119 150ug
DRUG:
PB-119 200ug
DRUG:
placebo
Sponsor
PegBio Co., Ltd.
Collaborators
[object Object]